Quantum BioPharma Targets MS with Novel Myelin Repair Drug

Quantum BioPharma Ltd., a biopharmaceutical company listed on NASDAQ under the ticker QNTM and on the CSE as QNTM, has announced its inclusion in a NetworkNewsAudio Audio Press Release that highlights its novel approach to treating multiple sclerosis (MS). The audio feature, titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” discusses the growing need for therapies that go beyond symptom management in a global MS therapeutics market projected to reach $38.62 billion by 2030. Quantum BioPharma's lead candidate, Lucid-MS, is a patented, first-in-class drug candidate designed to target the myelin sheath directly, with the goal of preventing, stopping, and potentially reversing its degradation. The company emphasizes that this therapy is intended to address the significant unmet need for disease-modifying treatments that can alter the course of multiple sclerosis.

To view the full press release, visit https://nnw.fm/eI6Gv. Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum focuses on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Additionally, Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop pharmaceutical and medical uses of similar products.

The news was disseminated through NetworkNewsWire (NNW), a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. NNW provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. This coverage highlights Quantum BioPharma's innovative approach to tackling a massive unmet need in MS, offering hope for patients who currently lack effective disease-modifying treatments. The company's focus on myelin repair represents a potential paradigm shift in MS therapy, moving beyond symptom management to potentially altering the disease's progression.